The Kovid-19 vaccine, developed by AstraZeneca and the University of Oxford, offered protection against other lineages of the virus to protect people against a new, more infectious coronavirus virus at similar levels, Oxford researchers said Paper released on Friday.
The paper, which has not yet been peer reviewed, stated that the vaccine had 74.6 percent efficacy against the new version, which was first found in Britain and Known as B.1.1.7. This was the same, although slightly lower than its efficacy against other lineages of the virus.
Preliminary, encouraging, findings suggest that all five of the leading vaccines may provide at least some protection against new variants of the virus spread worldwide. Nevertheless, increasing evidence suggests that mutant viruses may reduce the efficacy of vaccines, increasing the pressure on countries to vaccinate their populations as quickly as possible and reverse the changes occurring around the world.
Oxford scientists behind the vaccine took a weekly swab from the nose and throat of the participants enrolled in their clinical trials in Britain. To determine the vaccine’s efficacy against the new version, they sequenced viral particles from several hundred swabs between 1 October and 14 January, a period when the new version was present in the UK.
The vaccine had 84 percent efficacy against other lineages of the virus compared to the new variants, although the size of the small samples made a wide range of estimates.
Researchers also studied blood samples from clinical trial participants who had been vaccinated, and they determined that the variant might be more favorable in dodging antibodies generated by the vaccine.
The version, first revealed in Britain, has been reported in more than 70 other countries. Public Health England has estimated that the infection rate of variants is 25 percent to 40 percent higher than other forms of coronavirus.
Preliminary data from laboratory tests of vaccines Pfizer And modern It is suggested that they provide good protection against version B.1.1.7. Novavax, which sequenced test specimens from its clinical trial participants in the UK, while the version was widely circulating there, found that its vaccine was Best effective Against type B.1.1.7.
The paper released on Friday did not address the protective power of the AstraZeneca vaccine against another rapidly spreading coronavirus variant, known as B.1.351, was first identified in South Africa. Researchers are doing similar lab tests to try to measure that type of effect on the vaccine’s potential.
AstraZeneca vaccine has been authorized in about 50 countries around the world, but not in the United States, where the Food and Drug Administration awaits data from a clinical trial involving more than 30,000 participants, Most of which are American. Results from this month’s study could arrive, and AstraZeneca is expected to have sufficient safety data from the FDA to seek emergency authorization around the first week of March.
In the United States, the B.1.1.7 variant has been Identified in 33 states, But the full extent of its spread is unknown Lack of national monitoring program. Federal health officials have warned that it could become the dominant form of the virus in the United States by March.